The Plasma Levels of the Angiogenic Cytokine Endocan Are
Elevated in Patients with Multiple Myeloma

J 2018

The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma

STEINER, Normann, Roman HAJEK, Sabina ŠEVČÍKOVÁ, Bojana BORJAN, Gerold UNTERGASSER et. al.

Basic information

Original name

The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma

Authors

STEINER, Normann (40 Austria, guarantor), Roman HAJEK (203 Czech Republic), Sabina ŠEVČÍKOVÁ (203 Czech Republic, belonging to the institution), Bojana BORJAN (40 Austria), Gerold UNTERGASSER (40 Austria), Georg GOBEL (40 Austria) and Eberhard GUNSILIUS (40 Austria)

Edition

Anticancer Research, Athens, International Institute of Anticancer Research, 2018, 0250-7005

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Greece

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.935

RIV identification code

RIV/00216224:14110/18:00105233

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.21873/anticanres.12828

UT WoS

000449957600014

Keywords in English

Multiple myeloma; endocan; biomarker

Abstract

V originále

Background/Aim: Monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma often precede multiple myeloma (MM). The identification of biomarkers predicting progression to MM might facilitate an earlier diagnosis of MM. Our study assessed the diagnostic value of plasma levels of endocan, a 50-kDa soluble dermatan sulfate proteoglycan produced and secreted by endothelial cells, hitherto unknown in MM, in patients with plasma cell dyscrasia. Materials and Methods: Endocan levels were determined in 96 peripheral blood plasma samples by sandwich enzyme-linked immunosorbent assay (ELISA) in healthy controls (n=12), in patients with MGUS (n=17), and in patients newly diagnosed with (n=42) or relapsed/refractory (n=25) MM. Results: Median endocan concentration increased from MGUS (315.00 pg/ml) and healthy controls (316.19 pg/ml) to newly-diagnosed MM (371.82 pg/ml; p=0.027). The low endocan levels (median=246 .20 pg/ml) in patients with relapsed/refractory MM were similar to those in healthy controls and patients with MG US. A cut-off value of >220 pg/ml endocan in peripheral blood discriminated patients newly diagnosed with MM from those with MGUS (area under the curve(AUC)=0.66, 95% confidence interval(CI)=0.55-0.81). Conclusion: The plasma levels of endocan can non-invasively differentiate patients newly diagnosed with MM from those with MGUS and should therefore be evaluated prospectively as a potential diagnostic marker.

Citovat

STEINER, Normann, Roman HAJEK, Sabina ŠEVČÍKOVÁ, Bojana BORJAN, Gerold UNTERGASSER, Georg GOBEL and Eberhard GUNSILIUS. The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma. Anticancer Research. Athens: International Institute of Anticancer Research, 2018, vol. 38, No 9, p. 5087-5092. ISSN 0250-7005. Available from: https://dx.doi.org/10.21873/anticanres.12828.

@article{1483020,
   author = {Steiner, Normann and Hajek, Roman and Ševčíková, Sabina and Borjan, Bojana and Untergasser, Gerold and Gobel, Georg and Gunsilius, Eberhard},
   article_location = {Athens},
   article_number = {9},
   doi = {http://dx.doi.org/10.21873/anticanres.12828},
   keywords = {Multiple myeloma; endocan; biomarker},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   title = {The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma},
   volume = {38},
   year = {2018}
}

TY  - JOUR
ID  - 1483020
AU  - Steiner, Normann - Hajek, Roman - Ševčíková, Sabina - Borjan, Bojana - Untergasser, Gerold - Gobel, Georg - Gunsilius, Eberhard
PY  - 2018
TI  - The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma
JF  - Anticancer Research
VL  - 38
IS  - 9
SP  - 5087-5092
EP  - 5087-5092
PB  - International Institute of Anticancer Research
SN  - 02507005
KW  - Multiple myeloma
KW  - endocan
KW  - biomarker
N2  - Background/Aim: Monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma often precede multiple myeloma (MM). The identification of biomarkers predicting progression to MM might facilitate an earlier diagnosis of MM. Our study assessed the diagnostic value of plasma levels of endocan, a 50-kDa soluble dermatan sulfate proteoglycan produced and secreted by endothelial cells, hitherto unknown in MM, in patients with plasma cell dyscrasia. Materials and Methods: Endocan levels were determined in 96 peripheral blood plasma samples by sandwich enzyme-linked immunosorbent assay (ELISA) in healthy controls (n=12), in patients with MGUS (n=17), and in patients newly diagnosed with (n=42) or relapsed/refractory (n=25) MM. Results: Median endocan concentration increased from MGUS (315.00 pg/ml) and healthy controls (316.19 pg/ml) to newly-diagnosed MM (371.82 pg/ml; p=0.027). The low endocan levels (median=246 .20 pg/ml) in patients with relapsed/refractory MM were similar to those in healthy controls and patients with MG US. A cut-off value of >220 pg/ml endocan in peripheral blood discriminated patients newly diagnosed with MM from those with MGUS (area under the curve(AUC)=0.66, 95% confidence interval(CI)=0.55-0.81). Conclusion: The plasma levels of endocan can non-invasively differentiate patients newly diagnosed with MM from those with MGUS and should therefore be evaluated prospectively as a potential diagnostic marker.
ER  -

STEINER, Normann, Roman HAJEK, Sabina ŠEVČÍKOVÁ, Bojana BORJAN, Gerold UNTERGASSER, Georg GOBEL and Eberhard GUNSILIUS. The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma. \textit{Anticancer Research}. Athens: International Institute of Anticancer Research, 2018, vol.~38, No~9, p.~5087-5092. ISSN~0250-7005. Available from: https://dx.doi.org/10.21873/anticanres.12828.

Detailed Information on Publication Record